Stempoint Capital LP Has $10.45 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Stempoint Capital LP increased its position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 129.1% in the first quarter, Holdings Channel reports. The institutional investor owned 810,764 shares of the company’s stock after buying an additional 456,915 shares during the period. Eyepoint Pharmaceuticals comprises 2.0% of Stempoint Capital LP’s portfolio, making the stock its 14th biggest holding. Stempoint Capital LP’s holdings in Eyepoint Pharmaceuticals were worth $10,451,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. KBC Group NV bought a new stake in Eyepoint Pharmaceuticals in the 1st quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Eyepoint Pharmaceuticals by 51.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after acquiring an additional 1,358 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Eyepoint Pharmaceuticals during the 3rd quarter worth approximately $76,000. Tower Research Capital LLC TRC raised its holdings in shares of Eyepoint Pharmaceuticals by 218.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after purchasing an additional 5,967 shares during the last quarter. Finally, California State Teachers Retirement System raised its holdings in shares of Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after purchasing an additional 794 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Royal Bank Of Canada reduced their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Guggenheim reissued a “buy” rating and set a $68.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. Cantor Fitzgerald assumed coverage on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, July 8th. They set an “overweight” rating and a $47.00 price objective for the company. Stifel Nicolaus started coverage on Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Chardan Capital lifted their target price on Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $43.75.

Eyepoint Pharmaceuticals Stock Down 0.3%

Shares of Eyepoint Pharmaceuticals stock opened at $11.92 on Thursday. The stock has a market cap of $999.37 million, a P/E ratio of -3.41 and a beta of 1.73. Eyepoint Pharmaceuticals, Inc. has a 12-month low of $9.40 and a 12-month high of $19.11. The business’s 50 day moving average is $13.19 and its 200-day moving average is $13.92.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.20). The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. On average, sell-side analysts expect that Eyepoint Pharmaceuticals, Inc. will post -3.3 EPS for the current year.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.